Hjem
Ingeborg Margrethe Bachmanns bilde

Ingeborg Margrethe Bachmann

Professor
  • E-postIngeborg.Bachmann@uib.no
  • Telefon+47 55 97 31 60
  • Besøksadresse
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2022). Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. Current Oncology. 2193-2198.
  • Vis forfatter(e) (2019). Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. PLOS ONE. 1-18.
  • Vis forfatter(e) (2018). Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. Journal of the European Academy of Dermatology and Venereology. 1930-1939.
  • Vis forfatter(e) (2014). Nestin expression is associated with aggressive cutaneous melanoma of the nodular type. Modern Pathology. 396-401.
  • Vis forfatter(e) (2013). Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. Journal of Medical Genetics. 264-U82.
  • Vis forfatter(e) (2012). Tumor necrosis is a prognostic factor in thick cutaneous melanoma. American Journal of Surgical Pathology. 1477-1482.
  • Vis forfatter(e) (2012). Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 8699-8704.
  • Vis forfatter(e) (2012). Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma. Journal of Investigative Dermatology. 1247-1252.
  • Vis forfatter(e) (2010). Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 15 sider.
  • Vis forfatter(e) (2008). Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer. 362-372.
  • Vis forfatter(e) (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
  • Vis forfatter(e) (2008). Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Modern Pathology. 583-590.
  • Vis forfatter(e) (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
  • Vis forfatter(e) (2005). Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research. 8606-8614.
  • Vis forfatter(e) (2005). BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. Journal of Investigative Dermatology. 312-317.
  • Vis forfatter(e) (2004). Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. International Journal of Oncology. 1559-1565.
Vitenskapelig foredrag
  • Vis forfatter(e) (2022). Clinical versus punch biopsy assessment of BCC subtype and thickness within a PDT-setting.
Doktorgradsavhandling
  • Vis forfatter(e) (2007). Biological Markers in Cutaneous Melanoma. A study with special focus on cell cycle regulation, cell adhesion proteins and tumor necrosis.
Sammendrag/abstract
  • Vis forfatter(e) (2022). How well do experienced dermatologists clinically assess basal cell carcinoma subtype and thickness before treatment with photodynamic therapy? . Acta Dermato-Venereologica. 43-43.
  • Vis forfatter(e) (2007). Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. Virchows Archiv. 452-452.
Poster
  • Vis forfatter(e) (2022). How well do experienced dermatologists clinically assess basal cell carcinoma subtype and thickness before treatment with photodynamic therapy? .
  • Vis forfatter(e) (2022). Clinical versus histological assessment of basal cell carcinoma for photodynamic therapy .
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2013). Malignt melanom – diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den norske legeforening. 2154-2159.

Se fullstendig oversikt over publikasjoner i CRIStin.